profile image
@SharkAce I have worked with several Illumina products and instruments. They are definitely the market leader for next gen sequencing of relatively short pieces of DNA. I expect further growth, but the big boom is long gone, because the technology is no longer new.
•
1
•
profile image
@TheRealAurora Is there anything stopping you from investing?

It's not so easy to find the "right" share in the biotech sector. I find Illumina and USB SA very interesting purely in terms of their field of activity. But at the moment I don't have the time to read more about them.
••
profile image
@SharkAce I am put off by the price and I assume that the value will increase, but the company will either have to develop a new method or buy up other companies in order not to go under. Because at some point this one method will become technically obsolete. Maybe that will happen in 20 years. Or in two - I can't say. In my opinion, Illumina needs a second mainstay to remain relevant in the long term. Until I see that, I won't invest.
•
1
•
profile image
@SharkAce What are you currently looking for? A long-term investment or a hype like what happened with BioNTech?
••
profile image
@TheRealAurora thanks for your assessment :)

No, I'm not really interested in any hype. I would like to position myself in the bio tech sector with a single share and came across these two while browsing. I find neurology and DNA sequencing very exciting. But I won't make an investment until I'm more deeply involved in the subject :)
••
profile image
@SharkAce There is long-term growth at Merck and Thermo Fisher. Both companies have acquired several companies and divisions in recent decades. Another (German) company is QIAGEN, but it is smaller
••
profile image
@TheRealAurora I come across Thermo Fisher again and again. I think they are somehow represented everywhere in the healthcare sector
••
profile image
@SharkAce Yes, they have a very broad portfolio
••
profile image
@TheRealAurora would definitely be the more "relaxed" alternative :D
••